NGM Aims For Three Drugs In Clinical Trials, Padded By Cash From Merck
This article was originally published in The Pink Sheet Daily
Privately held NGM Biopharmaceuticals is investing in another dozen preclinical compounds, fueled in part by a rich deal with Merck & Co. that also enables employee expansion, Jeff Jonker explains in interview.
You may also be interested in...
EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.
NGM will not proceed with a Phase III study in F2/F3 NASH following failure to show fibrosis benefit in Phase IIb. Analysts say this setback could portend disappointing readouts for other NASH players.
No longer quiet NGM Bio unveils Phase II data at EASL showing rapid and significant reductions of hepatic fat, while Bristol announces a partnership to produce a non-invasive diagnostic for NASH and presents promising Phase II data for its FGF21 analogue.